Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals which address areas of unmet medical need.
Find out moreOur lead product, Ferric Maltol, is a novel oral ferric iron therapy approved by the FDA and will be marketed in the US as Accrufer® and is also approved by the EMA and Swiss Medic and marketed in the European Union as Feraccru® by our commercial partner, Norgine BV.
Find out moreRT @proactive_UK: Join us Tomorrow in Mayfair from 5:45pm at the Proactive One2One Investor Forum and meet @ShieldTx, @CIR_LSE , Faron Phar…
RT @proactive_UK: Join us at the Proactive One2One Investor Forum on Thursday 10th October and meet @CIR_LSE , @ShieldTx, Alliance Pharma &…
We are looking forward to the @proactive_UK One2One Investor Forum next week (10 Oct). Our CEO Carl Sterritt will b… https://t.co/qX9U6tPLEI
